XOMA Royalty Corporation has acquired biotechnology company Generation Bio for an undisclosed amount. This corporate acquisition signals XOMA's strategic expansion within the life sciences sector, integrating Generation Bio's innovative therapeutic platform.
Generation Bio is dedicated to transforming treatment possibilities for individuals with T cell-driven autoimmune diseases. The company’s core technology involves a novel modality of therapeutics that utilizes its T cell selective cell-targeted lipid nanoparticle (ctLNP) to deliver siRNA in vivo. This approach enables precise modulation of T cell activity, which is responsible for inflammation and auto-reactive tissue destruction. Generation Bio focuses on potent silencing of genes in T cells while aiming to spare the broader immune system.
For XOMA Royalty Corporation, a company focused on acquiring royalty streams and intellectual property rights in the biopharmaceutical industry, this acquisition is strategically important. Generation Bio’s pioneering ctLNP-siRNA technology and its potential for addressing significant unmet medical needs in autoimmune diseases represent a valuable asset. The synergy is expected to emerge from XOMA’s expertise in managing and monetizing life science assets, combined with Generation Bio's scientific innovation in targeted siRNA therapeutics.
The integration aims to leverage Generation Bio’s advancements in delivering genetic precision and tunable pharmacology of siRNA to T cells. The combined entity is positioned to accelerate the development and potential commercialization of these novel therapies, seeking to unlock further value from Generation Bio’s pipeline and scientific intellectual property in the competitive autoimmune disease landscape.